Key result
Pharmacological inhibition of Syk attenuated shear-induced platelet aggregation and reduced platelet-mediated thrombus formation by up to 50% under flow conditions.
Why the study?
Does Syk inhibition reduce shear-induced platelet aggregation and thrombus formation under pathophysiological shear stress?
Population
Isolated human platelets and whole blood
Comparison
Pathophysiological shear stress and… vs Physiological shear stress and untreated controls
Design
Preclinical
Authors
Loading...
Syk inhibition may attenuate shear-induced thrombosis in animal models; leaves open translation to clinical occlusive vascular disease.
Does Syk inhibition reduce shear-induced platelet aggregation and thrombus formation under pathophysiological shear stress?
Syk is a key molecule in shear-induced platelet aggregation and thrombus formation, suggesting its pharmacological inhibition may be a potential therapeutic target for occlusive vascular disease.
Speich et al. (2008) studied Shear-induced platelet aggregation. Syk inhibitors (piceatannol and OXSI-2) vs. Untreated/control was evaluated on Syk tyrosine phosphorylation and platelet-mediated thrombus formation. Pharmacological inhibition of Syk attenuated shear-induced platelet aggregation and reduced platelet-mediated thrombus formation by up to 50% under flow conditions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: